Novo Integrated Sciences, Inc.

NasdaqCM:NVOS Stock Report

Market Cap: US$3.4m

Novo Integrated Sciences Past Earnings Performance

Past criteria checks 0/6

Novo Integrated Sciences's earnings have been declining at an average annual rate of -46.6%, while the Healthcare industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 8.2% per year.

Key information

-46.6%

Earnings growth rate

-26.5%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate8.2%
Return on equity-251.9%
Net Margin-180.0%
Last Earnings Update31 May 2024

Recent past performance updates

Recent updates

Slammed 49% Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Screens Well Here But There Might Be A Catch

Jul 11
Slammed 49% Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Screens Well Here But There Might Be A Catch

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump

Apr 18
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump

Novo Integrated Sciences prices 4M unit public offering at $.50/unit

Oct 14

Novo Integrated Sciences expects to report over fivefold increase in Q3 revenue

Jul 11

Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?

Nov 23
Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Aug 07
Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Mar 02
Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Revenue & Expenses Breakdown

How Novo Integrated Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:NVOS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 May 2414-24160
29 Feb 2414-12150
30 Nov 2313-14150
31 Aug 2313-13140
31 May 231-32140
28 Feb 2312-35150
30 Nov 2212-35160
31 Aug 2212-33140
31 May 2223-12120
28 Feb 2211-9100
30 Nov 2110-590
31 Aug 219-480
31 May 218-7100
28 Feb 217-690
30 Nov 207-680
31 Aug 208-570
31 May 208-140
29 Feb 2010-140
30 Nov 1910040
31 Aug 199040
31 May 199-140
28 Feb 199-140
30 Nov 189-250
31 Aug 189-250
31 May 189-250
28 Feb 189-250
30 Nov 178-140
31 Aug 178-130
31 May 178-130
28 Feb 177020
30 Nov 167020
31 Aug 167020
31 Aug 157-230

Quality Earnings: NVOS is currently unprofitable.

Growing Profit Margin: NVOS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NVOS is unprofitable, and losses have increased over the past 5 years at a rate of 46.6% per year.

Accelerating Growth: Unable to compare NVOS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NVOS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (11.4%).


Return on Equity

High ROE: NVOS has a negative Return on Equity (-251.93%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies